MIG - Press Review

 

2020

Alternativer Text

Going Public Media -

AFFiRiS erhält Patent für Parkinson-Medikament in China

„Going Public“ reports about progresses of MIG portfolio company AFFiRiS. The biotech firm, based in Vienna, got a patent in China and will start a clinical study (Parkinson) in the second half of the year.
Find out more
Alternativer Text

Financial Times -

Ugur Sahin : the immunologist racing to find a vaccine

„Financial Times“ portrays Prof. Dr. Ugur Sahin, CEO of MIG portfolio company BioNTech, who started the race to find the first vaccine against SARS CoV-2.
Find out more
Alternativer Text

transkript, Finanzwelt und andere -

Immatics is planning a listing on the Nasdaq

Several national and international media are reporting about the IPO-plans of MIG portfolio company Immatics in Q2. on the Nasdaq.
Find out more
Find out more
Find out more
Alternativer Text

Reuters, Handelsblatt, FAZ -

BioNTech in China alliance with Fosun over coronavirus vaccine candidate

Newswire „Reuters“ reports about a cooperation of BioNTech, a MIG portfolio company. Together with Fosun Pharmaceutical a vaccine against Covid-19 should be developed first in China.
Find out more
Find out more
Find out more
Alternativer Text

Reuters -

Pfizer weighs working with BioNTech on potential coronavirus vaccine

Reuters reports, that Pfizer weighs working with MIG portfolio company BioNTech on a potential coronavirus vaccine.
Find out more
Alternativer Text

Finanzwelt -

Third Investment of MIG 16

Trade magazine „Finanzwelt“ reports about MIG Fonds newest investment in Neracare GmbH.
Find out more
Alternativer Text

OLED Brief -

Cynora introduces fluorescent blue emitter

Trade magazine „OLED-Brief“ reports about the first commercial OLED-product of Cynora, a MIG portfolio company.
Find out more
Alternativer Text

transkript -

Immatics closes second TCR-T-Billion Deal

Trade Magazine „transkript“ reports about a deal between immatics, a MIG porfolio company, and GlaxoSmithKline, which assures immatics milestone payments up to 1.1 Billion US Dollar.
Find out more
Alternativer Text

Finanzwelt -

„We align our portfolio along trends of the future“

„Finanzwelt“ reports about the year 2019 of MIG AG.
Find out more
Alternativer Text

Gründerszene -

„For me it would not be enough to sell shoes online“

Interview with Gloria Seibert, founder of Temedica, a new MIG portfolio company.
Find out more
Alternativer Text

transkript -

Advancecor achieves good data of Revacept

Trade magazine „transkript“ reports about a successful phase-II-study of biontech-firm AdvanceCOR, a MIG portfolio company.
Find out more
Alternativer Text

Wirtschaftswoche, Munich Start-up, Going Public Media, kma, Gründerszene -

Series B Funding of Temedica

Several media report about the 17 million Euro series-B-financing round of Temedica, which was led by MIG Fonds.
Find out more
Find out more
Find out more